The global Genetically modified mice Market is projected to grow from USD 1.70 billion in 2025 to USD 2.74 billion by 2030, registering a CAGR of 10.0% during the forecast period. Market growth is being driven by the increasing use of mice models in preclinical research, rising demand for genetically engineered disease models, growing adoption of personalized medicine, and advancements in genome-editing technologies such as CRISPR/Cas9. The increasing adoption of humanized mice, patient derived xenograft models, and genetically modified mice is further expanding opportunities across drug discovery and translational research.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
Growing Demand for Preclinical Models Drives Market Expansion
The increasing use of mice models in biomedical and pharmaceutical research is supporting sustained market growth. Mice share important genetic and physiological characteristics with humans, making them valuable for studying disease mechanisms, evaluating therapeutic candidates, and assessing treatment responses before clinical development.
Pharmaceutical and biotechnology companies are increasingly using specialized mouse models for drug discovery, toxicology, efficacy testing, disease modeling, and translational research. The growing complexity of therapeutic development is also increasing demand for disease-specific and genetically engineered models capable of reproducing specific human disease characteristics.
The adoption of humanized mice is particularly increasing in research areas where conventional mouse models cannot adequately reproduce human biological responses. Humanized mice can incorporate human cells, tissues, or immune components, providing researchers with more clinically relevant platforms for studying immunology, infectious diseases, oncology, and therapeutic responses.
Inbred Mice Segment Held the Largest Market Share
The inbred mice segment accounted for the largest share of the mice model market in 2024.
Inbred mice are produced through successive generations of controlled breeding, resulting in highly consistent genetic backgrounds. This genetic uniformity supports reproducibility across experiments and enables researchers to isolate specific genetic and biological variables.
These models are widely used in pharmacology, oncology, cardiovascular research, behavioral studies, tissue transplantation, carcinogenesis, and vaccine development.
Their reproducibility and established research applications make inbred mice an important component of pharmaceutical and academic preclinical research programs. At the same time, increasing demand for disease-specific research is encouraging the development and use of genetically modified mice with targeted genetic alterations.
CRISPR/Cas9 Technology Maintains Market Leadership
The CRISPR/Cas9 segment accounted for the largest share of the mice model market by technology in 2024.
The growing adoption of CRISPR/Cas9 is transforming the development of genetically modified mouse models by enabling targeted and efficient genome editing.
Unlike conventional approaches that may require multiple breeding generations, CRISPR/Cas9-based editing can introduce specific genetic modifications at an early developmental stage, potentially reducing the time required to generate customized models.
The technology supports gene knockouts, targeted mutations, gene insertions, multiplexed gene editing, and functional genomics, making it valuable for investigating disease pathways and identifying therapeutic targets.
CRISPR/Cas9 is also supporting the development of genetically modified mice that replicate disease-associated mutations more accurately. The expanding use of CRISPR-enabled models in oncology, neuroscience, immunology, rare diseases, and other therapeutic areas is expected to strengthen demand during the forecast period.
Humanized Mice and Patient Derived Xenograft Models Create New Opportunities
The growing focus on precision and personalized medicine is creating new opportunities for the mice model market. Researchers are increasingly developing models that replicate specific genetic mutations, human biological characteristics, and disease phenotypes to evaluate therapeutic responses in more representative settings.
Humanized mice are gaining importance in studies requiring human immune-system components or human-specific biological responses. These models are being used to evaluate immunotherapies, biologics, infectious disease treatments, and other advanced therapeutic approaches.
Similarly, patient derived xenograft (PDX) models are becoming increasingly important in oncology research. PDX models are developed by implanting patient-derived tumor tissue into immunodeficient mice, allowing researchers to investigate tumor growth, treatment response, disease progression, and therapeutic resistance.
The increasing use of patient derived xenograft models supports personalized oncology research by enabling researchers to evaluate potential treatment strategies using tumor characteristics derived from individual patients.
CROs and Pharmaceutical Developers Drive Model Adoption
Contract research organizations are playing an increasingly important role in the mice model ecosystem as pharmaceutical and biotechnology companies continue to outsource portions of their preclinical research activities.
CROs provide services ranging from breeding and model development to efficacy testing, pharmacology, and preclinical evaluation, enabling drug developers to access specialized facilities, expertise, and genetically engineered models without establishing extensive in-house infrastructure.
The growing outsourcing trend is also increasing demand for specialized humanized mice, patient derived xenograft models, and genetically modified mice for complex drug development programs. The combination of increasing drug development activity and greater reliance on external preclinical expertise is expected to support demand for mice model services globally.
North America Maintains Market Leadership
North America accounted for the largest share of the mice model market in 2024.
The region benefits from a well-established biomedical research ecosystem, substantial pharmaceutical and biotechnology investment, advanced research infrastructure, and the presence of leading mice model providers.
The US represents a major revenue contributor due to its concentration of pharmaceutical companies, biotechnology firms, CROs, academic institutions, and specialized research laboratories.
The presence of organizations providing genetically engineered models, breeding services, humanized mice, patient derived xenograft models, and preclinical research solutions further strengthens North America’s position in the global market.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1308
Advancements in Genetic Engineering Reshape the Market
Technological developments in genetic engineering are creating significant opportunities for mice model providers. The adoption of CRISPR/Cas9, microinjection, embryonic stem cell technologies, and other genome-engineering approaches enables researchers to develop increasingly sophisticated disease models.
These technologies are supporting the development of genetically modified mice for studying complex diseases, validating therapeutic targets, investigating molecular mechanisms, and evaluating treatment efficacy.
CRISPR/Cas9, in particular, enables researchers to introduce precise genetic modifications and develop models designed around specific disease-associated genes. These advances are improving the ability of researchers to reproduce human disease biology and support more targeted preclinical investigations.
As research moves toward more precise and clinically relevant disease modeling, demand for customized, genetically modified, humanized, and patient-derived mouse models is expected to increase.
Competitive Landscape
The mice model market includes specialized model developers, research organizations, CROs, and biotechnology companies competing through model customization, breeding capabilities, preclinical services, and technology development.
Key players profiled in the report include Charles River Laboratories, Inotiv, The Jackson Laboratory, JSR Corporation, Biocytogen, Trans Genic Inc., Harbour BioMed, genOway, GemPharmatech, Cyagen, Ozgene Pty Ltd., Taconic Biosciences, TransCure bioServices, Vivo Bio Tech Ltd., ingenious targeting laboratory, Janvier Labs, Champions Oncology, Inc., and Vitalstar Biotechnology Co., Ltd., among others.
Market participants are focusing on expanding genetically modified mice portfolios, developing disease-specific and patient derived xenograft models, increasing availability of humanized mice, strengthening preclinical service capabilities, and adopting advanced genome-editing technologies such as CRISPR/Cas9.
These developments are expected to enhance model customization, improve translational relevance, and support the growing demand for advanced preclinical research platforms worldwide.